HEPI Pharmaceuticals, Inc. Files Patent Application to Protect Potential Active Components of ProAlgaZyme(R)

Wednesday June 27, 8:00 am ET

SCOTTSDALE, AZ,--(MARKET WIRE)--Jun 27, 2007 -- HEPI Pharmaceuticals, Inc., a subsidiary of Health Enhancement Products, Inc. (OTC BB:HEPI.OB - News), the makers of ProAlgaZyme®, announced today the filing of a Provisional Application for Patent in the United States. The application is the result of recent discoveries building on research over the past several years on the chemical and biological analysis of ProAlgaZyme®. These discoveries, including newly identified components, shed light on recent results of clinical trials which indicate that ProAlgaZyme has the potential to reduce key markers of inflammation by 57% on average. The patent filing is designed to help protect the potential pharmaceutical opportunities represented by the potential active components of ProAlgaZyme®.

About ProAlgaZyme® and HEPI Pharmaceuticals, Inc.

ProAlgaZyme® is a nutraceutical product of Health Enhancement Products, Inc., the Company's parent, which is manufactured using only pure, all-natural ingredients. ProAlgaZyme® is a liquid product produced from algae grown in 100% distilled water. The liquid in which the algae are grown is drawn off, filtered, tested and bottled as ProAlgaZyme®. HEPI Pharmaceuticals, Inc., a wholly owned subsidiary of Health Enhancement Products, Inc., is focused on development of potential pharmaceutical opportunities represented by ProAlgaZyme®.

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, our inability to obtain regulatory approvals necessary to market and sell PAZ as a pharmaceutical, and the company's ability to secure funding, including for the subsidiary's pharmaceutical development of PAZ. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.